Interferon alfa-2a (DrugBank: Interferon alfa-2a, Interferon alfa)
6 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
25 | Progressive multifocal leukoencephalopathy | 0 |
26 | HTLV-1-associated myelopathy | 0 |
28 | Systemic amyloidosis | 0 |
56 | Behcet disease | 1 |
96 | Crohn disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03209219 (ClinicalTrials.gov) | June 30, 2017 | 4/7/2017 | Interferon a2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis | Randomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis | Behçet Disease;Uveitis | Drug: Interferon Alfa-2A;Drug: Cyclosporine Pill | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 36 | Phase 3 | China |